Impact of the adjustment of stratification factors on time-to-event analyses

06/27/2020
by   Madan G. Kundu, et al.
0

In a stratified clinical trial design with time to event end points, stratification factors are often accounted for the log-rank test and the Cox regression analyses. In this work, we have evaluated the impact of inclusion of stratification factors on the power of the stratified log-rank test and have compared the bias and standard error in HR estimate between multivariate and stratified Cox regression analyses through simulation. Results from our investigation suggests that both failing to consider stratification factor in presence of their prognostic effect and stratification with smaller number of events may substantially reduce the power of the log-rank test. Further, the HR estimate from the multivariate Cox analysis is more accurate and precise compared to the stratified Cox analysis. Our findings point towards the necessity of evaluating the impact of stratification factors on the time to event analyses at the time of study design which is presently not a norm.

READ FULL TEXT VIEW PDF
POST COMMENT

Comments

There are no comments yet.

Authors

page 1

page 2

page 3

page 4

09/20/2019

Alternative Analysis Methods for Time to Event Endpoints under Non-proportional Hazards: A Comparative Analysis

The log-rank test is most powerful under proportional hazards (PH). In p...
01/28/2022

Covariate-Adjusted Log-Rank Test: Guaranteed Efficiency Gain and Universal Applicability

Nonparametric covariate adjustment is considered for log-rank type tests...
11/13/2020

The Safe Log Rank Test: Error Control under Optional Stopping, Continuation and Prior Misspecification

We introduce the safe log rank test, a version of the log rank test that...
05/19/2020

A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching

In confirmatory cancer clinical trials, overall survival (OS) is normall...
03/03/2022

Censoring and censoring mechanisms in oncology in light of the estimands framework

In oncology clinical trials with time-to-event endpoints, censoring rule...
02/10/2021

Designing group sequential clinical trials when a delayed effect is anticipated: A practical guidance

A common feature of many recent trials evaluating the effects of immunot...
This week in AI

Get the week's most popular data science and artificial intelligence research sent straight to your inbox every Saturday.

References

  • [1] Kernan WN, Viscoli CM, Makuch RW, Brass LM, Horwitz RI. Stratified randomization for clinical trials. Journal of clinical epidemiology. 1999 Jan 1;52(1):19-26.
  • [2] Tu D, Shalay K, Pater J. Adjustment of treatment effect for covariates in clinical trials: statistical and regulatory issues. Drug Information Journal. 2000 Apr;34(2):511-23.
  • [3] International Conference on Harmonization. Statistical Principles for Clinical Trials (E9). 1998, http://academy.gmp-compliance.org/guidemgr/files/E9_GUIDELINE.PDF.
  • [4] Committee for Proprietary Medicinal Products. Committee for Proprietary Medicinal Products (CPMP) Point to consider on adjustment for baseline covariates. Statistics in medicine. 2004;23:701-9.
  • [5] Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. John Wiley & Sons; 2011 Jan 25.
  • [6] Cox DR. Regression models and life‐tables. Journal of the Royal Statistical Society: Series B (Methodological). 1972 Jan;34(2):187-202.
  • [7] Kang DH, Park SJ, Lee SA, Lee S, Kim DH, Kim HK, Yun SC, Hong GR, Song JM, Chung CH, Song JK. Early surgery or conservative care for asymptomatic aortic stenosis. New England Journal of Medicine. 2020 Jan 9;382(2):111-9.
  • [8] Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. New England Journal of Medicine. 2020 Feb 6;382(6):514-24.
  • [9] de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wülfing C, Kramer G, Eymard JC, Bamias A, Carles J, Iacovelli R. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. New England Journal of Medicine. 2019 Dec 26;381(26):2506-18.
  • [10] Paz-Ares L, Tan EH, O’byrne K, Zhang L, Hirsh V, Boyer M, Yang JH, Mok T, Lee KH, Lu S, Shi Y. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Annals of Oncology. 2017 Feb 1;28(2):270-7.
  • [11] Suntharalingam M, Winter K, Ilson D, Dicker AP, Kachnic L, Konski A, Chakravarthy AB, Anker CJ, Thakrar H, Horiba N, Dubey A. Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: the NRG oncology RTOG 0436 phase 3 randomized clinical trial. JAMA oncology. 2017 Nov 1;3(11):1520-8.
  • [12] Ng K, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM, Rubinson DA, Schrag D, Miksad R, Bullock AJ, Allen J. Effect of high-dose vs standard-dose vitamin D3 supplementation on progression-free survival among patients with advanced or metastatic colorectal cancer: the SUNSHINE Randomized Clinical Trial. Jama. 2019 Apr 9;321(14):1370-9.
  • [13] Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine. 2011 Feb 10;364(6):501-13.
  • [14] Touchefeu Y, Guimbaud R, Louvet C, Dahan L, Samalin E, Barbier E, Le Malicot K, Cohen R, Gornet JM, Aparicio T, Nguyen S. Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial. Gastric Cancer. 2019 May 1;22(3):577-86.
  • [15] Mohnike K, Steffen IG, Seidensticker M, Hass P, Damm R, Peters N, Seidensticker R, Schütte K, Arend J, Bornschein J, Streitparth T. Radioablation by image-guided (HDR) brachytherapy and transarterial chemoembolization in hepatocellular carcinoma: A Randomized phase II trial. Cardiovascular and interventional radiology. 2019 Feb 15;42(2):239-49.
  • [16] Wirsching HG, Tabatabai G, Roelcke U, Hottinger AF, Jörger F, Schmid A, Plasswilm L, Schrimpf D, Mancao C, Capper D, Conen K. Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. Annals of oncology. 2018 Jun 1;29(6):1423-30.
  • [17] AKAZAWA K, Nakamura T, Palesch Y. Power of logrank test and Cox regression model in clinical trials with heterogeneous samples. Statistics in medicine. 1997 16(5), pp.583-597.
  • [18] Feng C, Wang H, Tu XM. Power loss of stratified log-rank test in homogeneous samples. International Journal of Quality, Statistics, and Reliability. 2010.
  • [19] Hill C. Asymptotic relative efficiency of survival tests with covariates. Biometrika. 1981 Dec 1;68(3):699-702.
  • [20] Ding S, Sinha M. Evaluation of power of different Cox proportional hazards models incorporating stratification factors.